ArticleScientific reports2026
Statin use and the risk of liver-related events in older adults with steatotic liver disease.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Statins are widely used for cardiovascular prevention, yet their hepatic benefits in older adults with steatotic liver disease (SLD) remain uncertain, particularly regarding liver-related events (LREs) and the modifying role of cardiometabolic risk factors (CMRFs). This retrospective cohort study used data from the Korean National Health Insurance Service-Senior cohort, comprising 125,926 adults aged ≥ 60 years with fatty liver index ≥ 30, followed from 2011 to 2019. Participants with prior liver disease or LREs at baseline were excluded. Cumulative statin exposure quantified as cumulative defined daily dose (cDDD) and categorized as non-use, 1 cDDD to 89 cDDD, 90 cDDD to 364 cDDD, and ≥ 365 cDDD; statin intensity classified as low, moderate, or high. The primary outcomes were incident LREs (primary liver cancer, liver cirrhosis, and decompensated cirrhosis) identified using validated ICD-10 codes. Associations were assessed using Fine and Gray competing-risk models and expressed as subdistribution hazard ratios (SHRs). During a median follow-up of 9 years, 3,445 LREs occurred over 1,054,343 person-years. Statin use was associated with a dose-dependent reduction in LRE risk. Compared with non-users, participants with ≥ 365 cDDD had the lowest risk of total LREs (SHR, 0.69; 95% CI, 0.61–0.78), primary liver cancer (SHR, 0.63; 95% CI, 0.52–0.76), and liver cirrhosis (SHR, 0.66; 95% CI, 0.57–0.77). Moderate- to high-intensity statin conferred greater protection than low-intensity statin. Statin therapy was associated with a significant and dose-dependent reduction in the risk of LREs among older adults with SLD, including those aged ≥ 75 years.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.